Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

被引：0
|
作者：
Zhi Peng
Xingduo Hou
Yangmu Huang
Tong Xie
Xinyang Hua
机构：
[1] Peking University Cancer Hospital and Institute,Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)
[2] Peking University,School of Public Health
[3] Peking University,Department of Global Health, School of Public Health
[4] University of Oxford,Nuffield Department of Population Health
来源：
BMC Cancer | / 20卷
关键词：
Metastatic colorectal cancer; Cost-effectiveness analysis; Fruquintinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
    Peng, Zhi
    Hou, Xingduo
    Huang, Yangmu
    Xie, Tong
    Hua, Xinyang
    BMC CANCER, 2020, 20 (01)
  • [2] Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    TUMORI JOURNAL, 2020, 106 (05): : 400 - 405
  • [3] Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China
    Guan, Xin
    Li, Hongchao
    Xiong, Xiaomo
    Peng, Cike
    Wang, Ning
    Ma, Xiao
    Ma, Aixia
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 339 - 344
  • [4] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] COST EFFECTIVENESS OF FRUQUINTINIB VERSUS REGORAFENIB AS THE THIRD-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER IN CHINA
    Xin, G.
    Li, H. C.
    Peng, C.
    Wang, N.
    Ma, X.
    Xiong, X. M.
    Ma, A. X.
    VALUE IN HEALTH, 2019, 22 : S83 - S83
  • [6] Fruquintinib or regorafenib as the third-line treatments for metastatic colorectal cancer based on CONCUR and FRESCO trials: A cost-effectiveness analysis.
    Li, Qiu
    Zhang, Mengxi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Zhong, Jiayun
    Liu, Yu
    Fu, Qian
    Huang, Dan
    Gong, Wenjun
    Zou, Jian
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 593 - 602
  • [8] COST-EFFECTIVENESS ANALYSIS OF THE THIRD-LINE TREATMENT OF REGORAFENIB FOR METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS IN CHINA
    Wang, Y.
    Rui, M.
    Cao, Y. D.
    Fei, Z.
    Ma, A. X.
    Li, H. C.
    VALUE IN HEALTH, 2021, 24 : S28 - S28
  • [9] Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib
    Cheng, Y.
    Du, F. C.
    Fang, F. Q.
    Duan, Z. J.
    Lei, W.
    Shi, K. G.
    NEOPLASMA, 2020, 67 (06) : 1384 - 1390
  • [10] Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
    Kang, Dong-Won
    Lynn, Patricio B.
    Wang, Li
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS-OPEN, 2024, : 93 - 101
12345